EasthamJ. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol2007; 177: 17–24.
2.
IsraeliRSRyanCWJungLJ. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol2008; 179: 414–423.
3.
HeaneyRP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am1998; 27: 255–265.
KanisJAMcCloskeyEVJohanssonH. A reference standard for the description of osteoporosis. Bone2008; 42: 467–475.
6.
MiddletonETSteelSA. The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric2007; 10: 257–263.
7.
ShahinianBVKuoYFFreemanJL. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154–164.
8.
GreenspanSLCoatesPSereikaSM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab2005; 90: 6410–6417.
9.
SaadFAbrahamssonPAMillerK. Preserving bone health in patients with hormone-sensitive prostate cancer: The role of bisphosphonates. BJU Int2009; 104: 1573–1579.
10.
GilbertSMMcKiernanJM. The role of bisphosphonates in preventing skeletal complications of hormonal therapy. Urol Clin North Am2006; 33: 191–199.
11.
SmithMR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging2003; 20: 175–183.
12.
MichaelsonMDKaufmanDSLeeH. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol2007; 25: 1038–1042.
13.
HiganoCS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol2003; 21: 392–398.
